Общедоступные статьи - Camila I. de OliveiraПодробнее...
2 статьи недоступны нигде
10-valent pneumococcal conjugate vaccine (PCV10) decreases metabolic activity but not nasopharyngeal carriage of Streptococcus pneumoniae and Haemophilus influenzae
DC Andrade, IC Borges, ML Bouzas, JR Oliveira, KF Fukutani, AT Queiroz, ...
Vaccine 35 (33), 4105-4111, 2017
Финансирование: Research Foundation (Flanders)
A pilot and open trial to evaluate topical Bacterial Cellulose bio-curatives in the treatment of cutaneous leishmaniasis caused by L. braziliensis
FS Celes, HS Barud, SM Viana, PB Borba, PRL Machado, EM Carvalho, ...
Acta Tropica 225, 106192, 2022
Финансирование: Fundação de Amparo à Pesquisa do Estado de São Paulo
37 статей доступны в некоторых источниках
Immunity to a salivary protein of a sand fly vector protects against the fatal outcome of visceral leishmaniasis in a hamster model
R Gomes, C Teixeira, MJ Teixeira, F Oliveira, MJ Menezes, C Silva, ...
Proceedings of the National Academy of Sciences 105 (22), 7845-7850, 2008
Финансирование: US National Institutes of Health
Cytotoxic T cells mediate pathology and metastasis in cutaneous leishmaniasis
FO Novais, LP Carvalho, JW Graff, DP Beiting, G Ruthel, DS Roos, ...
PLoS pathogens 9 (7), e1003504, 2013
Финансирование: US National Institutes of Health
Topical amphotericin B in ultradeformable liposomes: Formulation, skin penetration study, antifungal and antileishmanial activity in vitro
AP Perez, MJ Altube, P Schilrreff, G Apezteguia, FS Celes, S Zacchino, ...
Colloids and Surfaces B: Biointerfaces 139, 190-198, 2016
Финансирование: Government of Argentina
Discovery of Markers of Exposure Specific to Bites of Lutzomyia longipalpis, the Vector of Leishmania infantum chagasi in Latin America
C Teixeira, R Gomes, N Collin, D Reynoso, R Jochim, F Oliveira, A Seitz, ...
PLoS neglected tropical diseases 4 (3), e638, 2010
Финансирование: US National Institutes of Health
Using Recombinant Proteins from Lutzomyia longipalpis Saliva to Estimate Human Vector Exposure in Visceral Leishmaniasis Endemic Areas
AP Souza, BB Andrade, D Aquino, P Entringer, JC Miranda, R Alcantara, ...
PLoS neglected tropical diseases 4 (3), e649, 2010
Финансирование: US National Institutes of Health
Towards a more precise serological diagnosis of human tegumentary leishmaniasis using Leishmania recombinant proteins
AP Souza, M Soto, JML Costa, VS Boaventura, CI de Oliveira, JR Cristal, ...
PLoS One 8 (6), e66110, 2013
Финансирование: Government of Spain
Immunity to Lutzomyia intermedia Saliva Modulates the Inflammatory Environment Induced by Leishmania braziliensis
TR de Moura, F Oliveira, GC Rodrigues, MW Carneiro, KF Fukutani, ...
PLoS neglected tropical diseases 4 (6), e712, 2010
Финансирование: US National Institutes of Health
PLGA nanoparticles loaded with KMP-11 stimulate innate immunity and induce the killing of Leishmania
DM Santos, MW Carneiro, TR de Moura, M Soto, NF Luz, DB Prates, ...
Nanomedicine: Nanotechnology, Biology and Medicine 9 (7), 985-995, 2013
Финансирование: Government of Spain
Evaluation of immune responses and analysis of the effect of vaccination of the Leishmania major recombinant ribosomal proteins L3 or L5 in two different murine models of …
L Ramírez, DM Santos, AP Souza, EAF Coelho, A Barral, C Alonso, ...
Vaccine 31 (9), 1312-1319, 2013
Финансирование: Government of Spain
Sand-Fly Saliva-Leishmania-Man: The Trigger Trio
F Oliveira, AM de Carvalho, CI de Oliveira
Frontiers in immunology 4, 375, 2013
Финансирование: US National Institutes of Health
Functional transcriptomics of wild-caught Lutzomyia intermedia salivary glands: identification of a protective salivary protein against Leishmania braziliensis infection
TR de Moura, F Oliveira, MW Carneiro, JC Miranda, J Clarêncio, ...
PLoS neglected tropical diseases 7 (5), e2242, 2013
Финансирование: US National Institutes of Health
Towards development of novel immunization strategies against leishmaniasis using PLGA nanoparticles loaded with kinetoplastid membrane protein-11
DM Santos, MW Carneiro, TR de Moura, K Fukutani, J Clarencio, M Soto, ...
International journal of nanomedicine, 2115-2127, 2012
Финансирование: Government of Spain
The microbiological signature of human cutaneous leishmaniasis lesions exhibits restricted bacterial diversity compared to healthy skin
VR Salgado, ATL Queiroz, SS Sanabani, CI Oliveira, EM Carvalho, ...
Memorias do Instituto Oswaldo Cruz 111 (4), 241-251, 2016
Финансирование: US National Institutes of Health
Glyburide, a NLRP3 inhibitor, decreases inflammatory response and is a candidate to reduce pathology in Leishmania braziliensis infection
AM Carvalho, FO Novais, CS Paixão, CI de Oliveira, PRL Machado, ...
Journal of Investigative Dermatology 140 (1), 246-249. e2, 2020
Финансирование: US National Institutes of Health
DNA vaccination with KMP11 and Lutzomyia longipalpis salivary protein protects hamsters against visceral leishmaniasis
RAA da Silva, NM Tavares, D Costa, M Pitombo, L Barbosa, K Fukutani, ...
Acta tropica 120 (3), 185-190, 2011
Финансирование: US National Institutes of Health
Cross-protective effect of a combined L5 plus L3 Leishmania major ribosomal protein based vaccine combined with a Th1 adjuvant in murine cutaneous and …
L Ramirez, L Corvo, MC Duarte, MA Chávez-Fumagalli, DG Valadares, ...
Parasites & vectors 7, 1-11, 2014
Финансирование: Government of Spain
Vaccination with a Leishmania infantum HSP70-II null mutant confers long-term protective immunity against Leishmania major infection in two mice models
JC SOLANA, L Ramirez, L CORVO, CI de OLIVEIRA, M BARRAL-NETTO, ...
PLoS Neglected Tropical Diseases, 2017
Финансирование: Government of Spain
Seroconversion to Lutzomyia intermedia LinB-13 as a biomarker for developing cutaneous leishmaniasis
AMP CARVALHO, K FUKUTANI, R SHARMA, RP CURVELO, ...
Scientific Reports, 2017
Финансирование: US National Institutes of Health
Информация о публикациях и финансировании собрана автоматически.